Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

PR Newswire

TARRYTOWN, N.Y., May 3, 2013

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ --Regeneron Pharmaceuticals, Inc.
(NASDAQ: REGN) today announced that it has expanded its ophthalmology
portfolio by acquiring full exclusive rights to two families of novel
antibodies invented at Regeneron and previously included in Regeneron's
antibody collaboration with Sanofi. Regeneron acquired full rights to
antibodies targeting the PDGF (platelet derived growth factor) family of
receptors and ligands in ophthalmology and all other indications and to
antibodies targeting the ANG2 (angiopoietin2) receptor and ligand in
ophthalmology. Antibodies to PDGF and ANG2 are currently in preclinical
development for use in ophthalmology.

With respect to PDGF antibodies, Regeneron will pay Sanofi $10 million
upfront, up to $40 million in development milestone payments, and royalties on
sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay
Sanofi $10 million upfront, a potential $5 million development milestone
payment, and royalties on sales.

Antibodies to ANG2 outside of ophthalmology will continue to be developed by
Regeneron and Sanofi under their antibody collaboration agreement, including
REGN910 (SAR 307746), an antibody to ANG2 that is currently in Phase 1
development in patients with advanced malignancies.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in
Tarrytown, New York that discovers, invents, develops, manufactures, and
commercializes medicines for the treatment of serious medical conditions.
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare
inflammatory condition and has product candidates in development in other
areas of high unmet medical need, including hypercholesterolemia, oncology,
rheumatoid arthritis, allergic asthma and atopic dermatitis. For additional
information about the company, please visit www.regeneron.com.

Regeneron Forward-Looking Statement
This news release includes forward-looking statements that involve risks and
uncertainties relating to future events and the future financial performance
of Regeneron, and actual events or results may differ materially from these
forward-looking statements. These statements concern, and these risks and
uncertainties include, among others, the nature, timing, and possible success
and therapeutic applications of Regeneron's products, product candidates, and
research and clinical programs now underway or planned, including without
limitation antibodies targeting ANG2 and PDGF; unforeseen safety issues
resulting from the administration of products and product candidates in
patients; the likelihood and timing of possible regulatory approval and
commercial launch of Regeneron's late-stage product candidates; determinations
by regulatory and administrative governmental authorities which may delay or
restrict Regeneron's ability to continue to develop or commercialize
Regeneron's products and product candidates; competing drugs and product
candidates that may be superior to Regeneron's products and product
candidates; uncertainty of market acceptance of Regeneron's products and
product candidates; the ability of Regeneron to manufacture and manage supply
chains for multiple products and product candidates; coverage and
reimbursement determinations by third-party payers, including Medicare and
Medicaid; unanticipated expenses; the costs of developing, producing, and
selling products; the ability of Regeneron to meet any of its sales or other
financial projections or guidance and changes to the assumptions underlying
those projections or guidance; the potential for any license or collaboration
agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare,
to be canceled or terminated without any further product success; and risks
associated with third party intellectual property and pending or future
litigation relating thereto. A more complete description of these and other
material risks can be found in Regeneron's filings with the United States
Securities and Exchange Commission, including its Form 10-K for the year ended
December 31, 2012. Regeneron does not undertake any obligation to update
publicly any forward-looking statement, including without limitation any
financial projection or guidance, whether as a result of new information,
future events, or otherwise, unless required by law.

Contact Information:
Manisha Narasimhan, Ph.D.        Peter Dworkin
Investor Relations               Corporate
                                 Communications
914.847.5126                     914.847.7640 
manisha.narasimhan@regeneron.com peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.

Website: http://www.regeneron.com